Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
High cortisol levels are found in severe mood disorders, particularly bipolar disorder. Hypercortisolaemia may cause or exacerbate both neurocognitive impairment and depressive symptoms. We hypothesized that antiglucocorticoid treatments, particularly corticosteroid receptor antagonists, would improve neurocognitive functioning and attenuate depressive symptoms in this disorder. To test this hypothesis, 20 bipolar patients were treated with 600 mg/day of the corticosteroid receptor antagonist mifepristone (RU-486) or placebo for 1 week in a double-blind crossover design. Over the total 6 weeks of the study, neurocognitive and neuroendocrine function were evaluated at baseline, days 21 and 42. Mood symptoms were evaluated weekly. Nineteen subjects completed the protocol; there were no drop-outs due to adverse events. Following treatment with mifepristone, selective improvement in neurocognitive functioning was observed. Spatial working memory performance was significantly improved compared to placebo (19.8% improvement over placebo). Measures of verbal fluency and spatial recognition memory were also improved after mifepristone. Beneficial effects on mood were found; Hamilton Depression Rating Scale scores were significantly reduced compared to baseline (mean reduction of 5.1 points) as were Montgomery-Asberg Depression Rating Scale scores (mean reduction of 6.05 points). No significant change occurred after placebo. These data require replication but provide preliminary evidence that glucocorticoid receptor antagonists may have useful cognitive-enhancing and possibly antidepressant properties in bipolar disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“drugs targeting the HPA axis can improve BD symptoms (Young et al. 2004;Young ,2014;Juruena et al. 2009).”
From The HPA axis in bipolar disorder: Systematic review and meta-analysis (2016) · cites this paper as Young et al. 2004
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“…symptomatic improvement, the antidepressant effect of mifepristone was the principal focus, therefore the outcome measures of interest were the 17-item Hamilton Depression Rating Scale (HDRS17; Hamilton, 1960) and the Montgomery–Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).”
MethodInfluentialKessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“Bipolar disorder is a chronic and recurrent illness, with a lifetime incidence of at least 1% (Kessler et al, 1994).”
BackgroundThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“Other secondary scales consisted of the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962) and the Young Mania Rating Scale (YMRS; Young et al, 1978).”
MethodNeuropsychological assessment.
Cipolotti, L., & Warrington, E. K. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.6.655 · Cited by 3,234
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
BackgroundGlucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016 · cited 2×
“It has been suggested that abnormalities in hypothalamic–pituitary– adrenal (HPA) axis function may cause or exacerbate both neurocognitive impairment and depressive symptoms (McQuade and Young, 2000; Sapolsky, 2000).”
BackgroundSmithson, M. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 1×
“Although the illness is defined by the occurrence of mania, the depressed phase predominates (Judd et al, 2002, 2003) and represents the greatest therapeutic challenge.”
Background
Research works printed but not linked: 5
- Cegalis J, Bowlin J (1991). Vigil: Software for the Assessment of Attention. Forthought: Nashua, NH.
- First MB, Spitzer RL, Williams JBW, Gibbon M (1995). Structured Clinical Interview for DSM-IV (SCID-I), Research Version. Biometrics Research Department, New York State Psychiatric Institute: New York.
- Høyberg ØJ, Wik G, Mehtonen OP, Peeters BWMM, Sennef C (2002). ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. Int J Neuropsychopharmacol 5: S148.
- Lopez JF, Little KY, Lopez-Figueroa AL, Lopez-Figueroa MO, Watson SJ (2003). Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry 53: 489.
- Thompson JM, Gray JM, Hughes J, Watson S, Ferrier I, Young AH (2000). A component process analysis of working memory dysfunction in bipolar affective disorder. J Psychopharmacol (Oxf) 14: A24.
Cited by
Items 101–200 of 315
Mind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 72
“An earlier, smaller scale trial by the same group showed improvements in both neurocognitive function and Frontiers in Pharmacology | Neuropharmacology December 2013 | Volume 4 | Article 158 | 4 depression rating scores (Young et al., 2004).”
ResultAerobic Physical Exercise as a Possible Treatment for Neurocognitive Dysfunction in Bipolar Disorder
Kucyi, A., Alsuwaidan, M. T., Liauw, S. S., & McIntyre, R. S. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2228 · Cited by 63
Goldstein, J. M., Holsen, L., Handa, R., & Tobet, S. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00247 · Cited by 63
“OPINION ARTICLE published: 08 September 2014 doi: 10.3389/fnins.2014.00247 Fetal hormonal programming of sex differences in depression: linking women’s mental health with sex differences in the brain across the lifespan”
BackgroundInfluentialOsuji, I. J., & Cullum, C. M. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.02.005 · Cited by 76
“In a treatment study of BPD, mifepristone (RU-486), a cortisol synthesis inhibitor, was found to improve verbal fluency compared with placebo but had no significant effect on working or verbal episodic memory [48].”
BackgroundSolomon, M. B., Wulsin, A. C., Rice, T., Wick, D., Myers, B., McKlveen, J., Flak, J. N., Ulrich-Lai, Y., & Herman, J. P. (2014) · Hormones and Behavior · doi:10.1016/j.yhbeh.2014.02.002 · Cited by 65
“Mifepristone is currently being advanced as a treatment option for many neuropsychiatric conditions associated with HPA axis dysregulation including major depression, psychotic depression and bipolar disorder (Belanoff et al., 2001; Belanoff et al., 2002; Young et al., 2004; Howland, 2013).”
BackgroundGlucocorticoid antagonists in neuropsychotic disorders
Schatzberg, A. F., & Lindley, S. E. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.001 · Cited by 69
Gallagher, P., Watson, S., Smith, M. S., Ferrier, I. N., & Young, A. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.017 · Cited by 61
Self-citationWatson, S., Thompson, J. M., Ritchie, J. C., Nicol Ferrier, I., & Young, A. H. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00280.x · Cited by 58
Self-citationPigot, M., Andrade, C., & FRANZCP, C. L. (2008) · The Journal of ECT · doi:10.1097/yct.0b013e3181616c14 · Cited by 57
“Mifepristone has also been found to reduce depression and improve cognition in bipolar disorder.(74)”
BackgroundHu, P., Oomen, C., van Dam, A.-M., Wester, J., Zhou, J.-N., Joëls, M., & Lucassen, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046224 · Cited by 58
“A similar quick switch may explain the rather rapid beneficial effects of mifepristone observed in a small sample of patients with psychotic depression [12,14,54,55].”
Molteni, R., Chourbaji, S., Brandwein, C., Racagni, G., Gass, P., & Riva, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108099815 · Cited by 57
Marić, N. P., & Adžić, M. (2013) · PubMed · Cited by 64
Mineralocorticoid receptor function and cognition in health and disease
Wingenfeld, K., & Otte, C. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.09.010 · Cited by 53
Medicating mood with maintenance in mind: bipolar depression pharmacotherapy
Malhi, G. S., Adams, D., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00711.x · Cited by 59
Steen, N. E., Methlie, P., Lorentzen, S., Hope, S., Barrett, E. A., Larsson, S., Mork, E., Almås, B., Løvås, K., Agartz, I., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06068yel · Cited by 52
Combination/augmentation strategies for improving the treatment of depression
Moret, C. (2005) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a798 · Cited by 70
“The delayed onset of action of serotonergic antidepressants is considered to be, at least in part, the result of a reduction in the function, or desensitization, of 5-HT 1A somatodendritic autoreceptors, which occurs following chronic treatment with these drugs.”
Akil, H. (2005) · Nature Medicine · doi:10.1038/nm0205-116 · Cited by 61
Spiga, F., Harrison, L. R., Wood, S. A., Atkinson, H. C., MacSweeney, C. P., Thomson, F., Craighead, M., Grassie, M., & Lightman, S. L. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2007.01605.x · Cited by 53
Golier, J. A., Caramanica, K., Michaelides, A. C., Makotkine, I., Schmeidler, J., Harvey, P. D., & Yehuda, R. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.001 · Cited by 53
“isorder, one week of treatment with 600 mg/day improved spaial working memory (Young et al., 2004; Watson et al., 2012).”
The effect of vitamin B6 on dexamethasone-induced depression in mice model of despair
Mesripour, A., Alhimma, F., & Hajhashemi, V. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1442184 · Cited by 52
Jacquot, C., Croft, A. P., Prendergast, M. A., Mulholland, P., Shaw, S. G., & Little, H. J. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00799.x · Cited by 49
Kling, M. A., Coleman, V. H., & Schulkin, J. (2009) · Depression and Anxiety · doi:10.1002/da.20546 · Cited by 52
“Another study[28] examined the effects of corticosteroid receptor antagonists on mood and neurocognitive functioning in bipolar disorder.”
BackgroundNeuropharmacology of glucocorticoids: Focus on emotion, cognition and cocaine
de Kloet, E. R., de Jong, I. E. M., & Oitzl, M. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.011 · Cited by 56
“The hypothalamic pituitary adrenal (HPA) axis representing the hormonal branch of the stress system has two modes of operation: first, it coordinates through an ultradian rhythm of hourly pulses in HPA axis activity daily and sleep-related events; the pulses increase in amplitude towards the daily (or nightly) activit…”
BackgroundMajor depression: emerging therapeutics
Sen, S., & Sanacora, G. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20043 · Cited by 47
Zhang, Y.-P., Wang, H.-Y., Zhang, C., Liu, B.-P., Peng, Z.-L., Li, Y.-Y., Liu, F.-M., & Song, C. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.03.033 · Cited by 49
Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder
Chakrabarty, T., Torres, I. J., Bond, D. J., & Yatham, L. N. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.018 · Cited by 45
Karst, H., & Joëls, M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301296 · Cited by 55
“…and (ii) if so, whether this can be normalized by 4-days treatment with the GR-antagonist RU 38486, a compound that was recently described to rapidly ameliorate symptoms of bipolar or psychotic depression in humans (Belanoff et al, 2001; Young et al, 2004; Simpson et al, 2005; Flores et al, 2006).”
BackgroundResultInfluentialTerfehr, K., Wolf, O. T., Schlosser, N., Fernando, S. C., Otte, C., Muhtz, C., Beblo, T., Drießen, M., Spitzer, C., Löwe, B., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2117-z · Cited by 51
Gregory, S., Hill, D., Grey, B., Ketelbey, W., Miller, T., Muniz-Terrera, G., & Ritchie, C. W. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154246 · Cited by 45
Gallagher, P., & Young, A. H. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a811 · Cited by 47
“Utilizing the same experimental design as described above (Young et al 2004), we have recently completed the first trial to examine the efficacy of adjunctive mifepristone administration in schizophrenia (Gallagher et al 2005).”
Self-citationSalvat-Pujol, N., Labad, J., Urretavizcaya, M., de Arriba-Arnau, A., Segalàs, C., Real, E., Ferrer, A., Crespo, J. M., Jiménez-Murcia, S., Soriano-Mas, C., et al. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.007 · Cited by 47
Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments
Porter, R. J., & Gallagher, P. (2006) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2006.00152.x · Cited by 45
“A recent study investigated aGR antagonist in the treatment of bipolar depression, in a double-blind, placebo-controlled crossover design (186).”
BackgroundSelf-citationElevated fingernail cortisol levels in major depressive episodes
Herane-Vives, A., Fischer, S., de Angel, V., Wise, T., Cheung, E., Chua, K.-C., Arnone, D., Young, A. H., & Cleare, A. J. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.10.026 · Cited by 46
“If the impaired cognition in patients with histories of more severe depression is linked to hypercortisolism, this raises the possibility that drugs such as mifepristone, a specific glucocorticoid receptor blocker, may have a therapeutic benefit in this neurocognitive impairment (Young et al. 2004).”
BackgroundSelf-citationYau, J. L. W., Noble, J., Thomas, S., Kerwin, R., Morgan, P. E., Lightman, S., Seckl, J. R., & Pariante, C. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301389 · Cited by 46
“Third, drugs that directly regulate HPA axis activity have therapeutic effects in affective disorders (Nemeroff and Owens, 2002; Young et al, 2004; Flores et al, 2006).”
BackgroundMackin, P., Gallagher, P., Watson, S., Young, A. H., & Nicol Ferrier, I. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701213211 · Cited by 45
“Details of the mifepristone treatment protocol have been described previously [11,12].”
BackgroundMethodSelf-citationKingdon, D., & Young, A. H. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.035675 · Cited by 51
“Drugs which counteract the effects of corticosteroids show promise as treatments in mood disorders (Young et al, 2004).”
BackgroundSelf-citationLombardo, G., Enache, D., Gianotti, L., Schatzberg, A. F., Young, A. H., Pariante, C. M., & Mondelli, V. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104420 · Cited by 45
“, 1995) focused on morning blood collection, three studies (Belanoff et al., 2002; Wolkowitz et al., 1999; Young et al., 2004) focused on afternoon blood collection, one study (Flores et al.”
BackgroundMethodSelf-citationA Pilot Study of Mifepristone in Combat-Related PTSD
Golier, J. A., Caramanica, K., DeMaria, R., & Yehuda, R. (2012) · Depression Research and Treatment · doi:10.1155/2012/393251 · Cited by 48
“Preliminary data suggest that short-term administration of high doses of mifepristone can have beneficial effects in other neuropsychiatric conditions [3, 8–10], but to date mifepristone has not been studied in PTSD.”
BackgroundGallagher, P., Reid, K. S., & Ferrier, I. N. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.018 · Cited by 46
Self-citationEarly life stress-induced alterations in rat brain structures measured with high resolution MRI
Sarabdjitsingh, R. A., Loi, M., Joëls, M., Dijkhuizen, R. M., & van der Toorn, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185061 · Cited by 48
The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder
Kidnapillai, S., Bortolasci, C. C., Udawela, M., Panizzutti, B., Spolding, B., Connor, T., Sanigorski, A. J., Dean, O. M., Crowley, T. M., Jamain, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1492734 · Cited by 45
Bipolar disorder: candidate drug targets
Zarate, C. A., & Manji, H. K. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20042 · Cited by 45
The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets
Ascoli, B. M., Géa, L. P., Colombo, R., Barbé-Tuana, F. M., Kapczinski, F., & Rosa, A. R. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416642846 · Cited by 40
“In addition, the use of a GR antagonist (mifepristone RU-486) has been shown to be effective in improving cognitive function in bipolar patients (Young et al., 2004).”
BackgroundPost-traumatic stress disorder: emerging concepts of pharmacotherapy
Baker, D. G., Nievergelt, C. M., & Risbrough, V. B. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902972494 · Cited by 40
“Small studies (n = 30) of psychotic depression and bipolar disorder thus far using a non-selective glucocorticoid receptor antagonist mifepristone (RU-486), otherwise known as the morning after pill, are reported to show promise in reducing cognitive disruption and psychosis [138,139].”
BackgroundPersistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia
Gallagher, P., Watson, S., Dye, C. E., Young, A. H., & Ferrier, I. N. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.12.005 · Cited by 45
“The study formed part of a research program examining the efficacy of glucocorticoid antagonists in schizophrenia and bipolar disorder, the results of which are reported elsewhere (Gallagher et al., 2005; Young et al., 2004).”
BackgroundMethodSelf-citationAssociation between cortisol awakening response and memory function in major depression
Hinkelmann, K., Muhtz, C., Dettenborn, L., Agorastos, A., Moritz, S., Wingenfeld, K., Spitzer, C., Gold, S. M., Wiedemann, K., & Otte, C. (2013) · Psychological Medicine · doi:10.1017/s0033291713000287 · Cited by 38
“2009) or improved memory function in depressed bipolar patients after blocking the glucocorticoid receptor (Young et al. 2004; Watson et al. 2012).”
BackgroundAntiglucocoticoid Treatments for Depression
Young, A. H. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01813.x · Cited by 36
“In a recent pilot study, 20 subjects with bipolar disorder were treated with 600 mg day − 1 of RU486 or placebo for 1 week in a double-blind crossover design [24].”
MethodSelf-citationCortisol awakening response and spatial working memory in man: a U‐shaped relationship
Moriarty, A. S., Bradley, A. J., Anderson, K. N., Watson, S., Gallagher, P., & McAllister-Williams, H. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2399 · Cited by 40
“Moreover, in patients with bipolar disorder, which is associated with hypothalamic–pituitary– adrenal (HPA)-axis dysregulation, spatial working memory (SWM) has been shown to improve with antiglucocorticoid treatment (Young et al., 2004).”
BackgroundSelf-citationTamura, J. K., Carvalho, I. P., Lui, L. M. W., Feng, J. N., Rosenblat, J. D., Mansur, R. B., Lee, Y. L., Cha, D. S., Teopiz, K. M., Ahmad, Z., et al. (2021) · CNS Spectrums · doi:10.1017/s1092852921000092 · Cited by 39
Gong, Y., Sun, X., Wu, F., Su, C., Ding, J., & Hu, G. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00324.x · Cited by 36
“High levels of GR in the brain would promote anxietylike behavior [56], and the blockade of GR leads to improvements in cognition and mood in patients with bipolar disorder [57].”
BackgroundWang, D., Lin, W., Pan, Y., KUANG, X.-Y., Qi, X., & Sun, H. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.01.011 · Cited by 36
Emerging drugs for major depressive disorder
Kennedy, S. H., & Rizvi, S. J. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903107751 · Cited by 39
“The drug is also under investigation for bipolar depression [88,139] and several Phase II trials with Org 34517, a GR antagonist, have recently been completed.”
BackgroundZhang, Q., Yang, H., Wang, J., Li, A., Zhang, W., Cui, X., & Wang, K. (2013) · Nutrition Journal · doi:10.1186/1475-2891-12-84 · Cited by 36
“Clinically effective antidepressant medications exert their therapeutic actions partially by modulating HPA function through the regulation of receptor expression, subsequently ameliorating many of the behavioral disturbances associated with depressive-like states [26,27].”
Backgroundvan Gemert, N. G., & Joëls, M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01472.x · Cited by 38
Cognitive correlates of hypothalamic–pituitary–adrenal axis in major depression
Schlosser, N., Wolf, O. T., & Wingenfeld, K. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.79 · Cited by 33
Steen, N. E., Lorentzen, S., Barrett, E. A., Lagerberg, T. V., Hope, S., Larsson, S., Berg, A. O., Agartz, I., Melle, I. S., Berg, J. P., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.008 · Cited by 36
Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Lewis, G. F., Leiter, L. A., MacQueen, G. M., Miranda, A., Fulgosi, D., Konarski, J. Z., & Kennedy, S. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1615 · Cited by 32
“5 Glucocorticoids: a salient mediator in mood disorders Abnormalities in hypothalamic–pituitary–adrenal (HPA) axis function may engender or exacerbate cognitive impairment and depressive symptoms [93-96] .”
BackgroundGreen, M. J., Raudino, A., Cairns, M. J., Wu, J. Q., Tooney, P. A., Scott, R. J., & Carr, V. J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.019 · Cited by 40
“These may form the basis of new treatments for cognition; indeed, one previous study shows positive effects of manipulation of glucocorticoid receptor (GR) function on cognitive performance in bipolar disorder (Young et al., 2004); however, interestingly, a similar study of GR manipulation in schizophrenia which was n…”
Bipolar Disorder: Clinical Perspectives and Implications with Cognitive Dysfunction and Dementia
Lopes, R., & Fernandes, L. P. N. S. (2012) · Depression Research and Treatment · doi:10.1155/2012/275957 · Cited by 35
Spijker, A. T., Giltay, E. J., van Rossum, E. F. C., Manenschijn, L., DeRijk, R. H., Haffmans, J., Zitman, F. G., & Hoencamp, E. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.03.020 · Cited by 30
“Furthermore, the clinical relevance of these findings has become clear in the therapeutic effect of GR-antagonists, like mifepristone, improving mood and neurocognitive functioning in bipolar depression (Young et al., 2004).”
BackgroundAdolescence, glucocorticoids and alcohol
Prendergast, M., & Little, H. J. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.07.008 · Cited by 34
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 32
“One 6-week pilot study found that 600 mg/day of RU-486 improved depressive symptoms and cognition over placebo [83], and that this cognitive improvement was inversely associated with basal cortisol levels, suggesting an antiglucocorticoid effect.”
BackgroundWróbel, A., Serefko, A., Właź, P., & Poleszak, E. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.008 · Cited by 36
“…use of the glucocorticoid receptor antagonists could be beneficial in the treatment of mood disorders (Belanoff et al., 2002; Murphy et al., 1993; Young et al., 2004), while on the other, the administration of antidepressant therapy efficiently normalizes the disturbed cortisol circulation and…”
BackgroundMcCutcheon, J. E., Fisher, A. S., Guzdar, E., Wood, S. A., Lightman, S. L., & Hunt, S. P. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06043.x · Cited by 33
Antiglucocorticoid and related treatments for psychosis
Garner, B., Phillips, L. J., Bendall, S., & Hetrick, S. E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006995.pub2 · Cited by 27
Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia
Nagaraja, N., Andrade, C., Suresh, S., Singh, N. M., Chandra, J. S., & Venkataraman, B. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0593-y · Cited by 28
“In bipolar patients, mifepristone treatment for 1 week reduced measures of depression and improved cognitive performance (Young et al. 2004); in this study, however, it is not clear whether the improvement in cognition was due to antagonism of glucocorticoid receptors or to the improvement in depression, per se.”
BackgroundChen, J., Fang, Y., Kemp, D. E., Calabrese, J. R., & Gao, K. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0157-z · Cited by 30
“The corticosteroid receptor antagonist mifepristone (RU-486) was superior to placebo in reducing depressive symptom in BPD [24].”
BackgroundGómez-Lázaro, E., Garmendia, L., Beitia, G., Pérez-Tejada, J., Azpiroz, A., & Arregi, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.019 · Cited by 30
“Thus, in this case, the blocking of GRs may constitute a more appropriate mechanism for inducing an antidepressant effect (DeBattista et al., 2006; Flores et al., 2006; Young et al., 2004).”
Żabińska, M., Wiśniewska, K., Węgrzyn, G., & Pierzynowska, K. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107070 · Cited by 29
“For this reason, agonists and antagonists have been tested for multiple receptors that may play an important role in cognitive dysfunction (Sol ´ e et al., 2017; Young et al., 2004).”
BackgroundStress, Schizophrenia and Bipolar Disorder
Green, M. J., Girshkin, L., Teroganova, N., & Quidé, Y. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_290 · Cited by 29
Kolber, B. J., & Muglia, L. J. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.061 · Cited by 32
“Investigators have begun using pharmaceuticals that alter activity of GRs with some success in clinical trials (Murphy et al., 1993; Young et al., 2004).”
BackgroundLenze, E. J., Dixon, D. J., Mantella, R. C., Doré, P., Andreescu, C., Reynolds, C. F., Newcomer, J. W., & Butters, M. A. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2732 · Cited by 29
“Therefore, future research in this area should examine treatments, pharmacologic (Young et al., 2004) or psychotherapeutic (Peavy, 2008), that more specifically block cortisol’s central nervous system effects.”
BackgroundYoung, A. H. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000020 · Cited by 25
“Our previous work has shown that neurocognitive abnormalities in BD benefit from brief administration of the glucocorticoid antagonist mifepristone (RU-486).(22,23) This finding opens the possibility of future drug development along these lines, aimed at targeting cognitive impairments in BD, which appear to progress…”
BackgroundSelf-citationTreatment of Bipolar Depression
Dubovsky, S. L. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.02.003 · Cited by 25
Association between NR3C1 rs41423247 polymorphism and depression: A PRISMA-compliant meta-analysis
Peng, Q., Yan, H., Wen, Y., Lai, C., & Shi, L. (2018) · Medicine · doi:10.1097/md.0000000000012541 · Cited by 28
An update on potential pharmacotherapies for cognitive impairment in bipolar disorder
Johnson, D. E., McIntyre, R. S., Mansur, R. B., & Rosenblat, J. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2194488 · Cited by 25
“Spatial working memory, verbal fluency, and spatial recognition memory were improved two weeks post-treatment [115].”
BackgroundDonoghue, K., Rose, A., Coulton, S., Milward, J., Reed, K., Drummond, C., & Little, H. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0757-1 · Cited by 23
“A clinical pilot study found mifepristone alleviated both the cognitive deficits and the depressive symptoms in bipolar depression [35].”
BackgroundWilliams, S., & Ghosh, C. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.009 · Cited by 26
Spiga, F., Knight, D. M., Droste, S. K., Conway-Campbell, B. L., Kershaw, Y. M., MacSweeney, C. P., THOMSON, F. J., Craighead, M. W., Peeters, B. W. M. M., & Lightman, S. L. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109348175 · Cited by 25
“Clinical data have shown that RU486 exerts therapeutic effects in the treatment of cognitive dysfunction in bipolar disorder (Young et al., 2004), although its therapeutic potential is still controversial (Nihalani and Schwartz, 2007).”
BackgroundThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase
Brooks, S. P., Croft, A. P., Norman, G., Shaw, S., & Little, H. J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.010 · Cited by 23
Lenze, E., Hershey, T., Newcomer, J., Karp, J., Blumberger, D., Anger, J., Dore, P. M., & Dixon, D. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4085 · Cited by 19
“…anxiety, possibly because impairment in these cognitive domains contributes to treatment resistance in anxiety disorders (Caudle et al., 2007) or because HPA dysfunction directly interferes with the effects of antidepressants (Young et al., 2004b; Ising et al., 2007; Juruena et al., 2009).”
BackgroundOh, H.-M., Lee, J., Kim, S.-W., Oh, Y.-T., Kim, W., Lee, S.-B., Cho, Y.-R., Jeon, Y.-J., Cho, J.-H., & Son, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01674 · Cited by 24
“One clinical study reported the positive effects of mifepristone, a GR antagonist (Young et al., 2004).”
BackgroundSRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders
Steen, N. E., Tesli, M., Kähler, A. K., Methlie, P., Hope, S., Barrett, E. A., Larsson, S., Mork, E., Løvås, K., Røssberg, J. I., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.013 · Cited by 24
Pekary, A. E., Stevens, S. A., & Sattin, A. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.10.003 · Cited by 23
Phenytoin: an anti-bipolar anticonvulsant?
Bersudsky, Y. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006140 · Cited by 23
Rapid Computerized Assessment of Neurocognitive Deficits in Bipolar Disorder
Iverson, G. L., Brooks, B. L., & Young, A. H. (2009) · Applied Neuropsychology · doi:10.1080/09084280903098778 · Cited by 21
“Increasingly, there is an interest in identifying medications that can effectively treat the symptoms of bipolar disorder and improve cognition (Khan et al., 2004; Young et al., 2004).”
BackgroundSelf-citationKennedy, S. H., Young, A. H., & Blier, P. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.048 · Cited by 20
“, 1993), corticotropin releasing factor (CRF), which mediates neuroendocrine, immune, behavioral, and autonomic responses to stress (Holsboer and Ising, 2008), and the glucocorticoid receptor, GR2 (Young et al., 2004).”
BackgroundSelf-citationGallagher, P., Gray, J. M., & Kessels, R. P. C. (2014) · Psychological Medicine · doi:10.1017/s0033291714001676 · Cited by 23
“2008) and specifically improves visuo-spatial memory (Young et al. 2004; Watson et al. 2012).”
Self-citationEmerging drugs for bipolar disorder
Sanches, M., Newberg, A. B., & Soares, J. C. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.492393 · Cited by 21
“In this sense, a recent double-blind, placebo-controlled study analyzed the effects of mifeprestone, an antagonist of cortisol receptors, on bipolar depression [77].”
BackgroundVisual Memory Performance in Patients with Major Depression: A 9-Month Follow-Up
Hammar, Å., & Schmid, M. T. (2013) · Applied Neuropsychology Adult · doi:10.1080/09084282.2012.670170 · Cited by 22
“Memory is a cognitive function that has been of interest in depression research because patients with major depressive disorder (MDD) often self-report that they experience poor memory functioning when depressed (Kalska, Punamäki, Mäkinen-Pelli, & Saarinen, 1999; Young et al., 2004).”
BackgroundWatson, S., Thompson, J. M., Malik, N., Nicol Ferrier, I., & Young, A. H. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01560.x · Cited by 19
Self-citationThe Role of the Adrenal–Gut–Brain Axis on Comorbid Depressive Disorder Development in Diabetes
Mázala-de-Oliveira, T., da Silva, B. P. B., Campello‐Costa, P., & Carvalho, V. F. (2023) · Biomolecules · doi:10.3390/biom13101504 · Cited by 20
“In fact, treatment with mifepristone improved neurocognitive impairment in bipolar depressed patients [111].”
BackgroundYoung, K. D., Preskorn, S., Victor, T. A., Misaki, M., Bodurka, J., & Drevets, W. C. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw036 · Cited by 20
“…examine such a measure was performed in patients with bipolar disorder, which found improved spatial working memory and verbal fluency in these patients following mifepristone relative to placebo administration, while only small improvements were observed in clinical ratings (Young et al., 2004).”
ResultIntracellular Signaling Cascades in Bipolar Disorder
Jones, G. H., Rong, C., Shariq, A. S., Mishra, A. P., & Machado‐Vieira, R. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_157 · Cited by 19
Qi, C., Shu, Y., Chen, F.-H., Ding, Y., & Zhou, J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.12.009 · Cited by 18
Mechanisms of depression: role of the HPA axis
Eede, F. V. D., & Claes, S. J. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.11.021 · Cited by 20
Ponsoni, A., Branco, L. D., Cotrena, C., Shansis, F., & Fonseca, R. P. (2021) · Applied Neuropsychology Adult · doi:10.1080/23279095.2021.1979551 · Cited by 20
“In MDD, some studies report no change in working memory performance (O ’ Brien et al., 2004), while others note improvement (Young et al., 2004).”
MethodGuerrin, C. G. J., Shoji, A., Doorduin, J., & de Vries, E. F. J. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01723-3 · Cited by 19
“These results are consistent with clinical data indicating anxiety and impaired recognition memory in schizophrenia [37, 38] and other neurodevelopmental disorders such as autism [39, 40], and bipolar disorder [41, 42].”
ResultChapter 4. Psychoneuroendocrinology
Sforzini, L., Weston, F. I., & Pariante, C. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as04 · Cited by 16
Metadata
- Authors
- Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Young, Allan H
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-05
- Volume
- 29
- Issue
- 8
- Pages
- 1538-1545
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2041573038
- Cited by
- 318
- References
- 38
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 2 · 2021: 11 · 2020: 9 · 2019: 5 · 2018: 14 · 2017: 8 · 2016: 16 · 2015: 13 · 2014: 18 · 2013: 12 · 2012: 14
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Stanley Medical Research Institute
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, RU486, bipolar disorder, glucocorticoid receptor antagonist, hypercortisolism, neurocognitive function, spatial working memory, verbal fluency, spatial recognition memory, depressive symptoms, antidepressant effects, cognitive enhancement
- MeSH terms
- Adult, Affect, Attention, Bipolar Disorder, Cognition, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Learning, Male, Memory, Short-Term, Middle Aged, Psychiatric Status Rating Scales, Psychomotor Performance, Receptors, Glucocorticoid, Space Perception, Verbal Learning, Mifepristone, Treatment Outcome, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.